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ABSTRACT
Background: Glaucoma, globally the second most 
common cause of  blindness and the commonest cause of  
preventable visual disability, is a progressive 
neurodegenerative disease of  the retinal ganglion cells and 
their axons .Neuroprotection is an evolving area in the 
management of  glaucoma. This review aims to highlight 
the current neuroprotective agents under investigation and 
the promise they hold for future management of  glaucoma.
Method: The available literature on the use of  
Neuroprotection in Glaucoma was reviewed using 
available journals and internet based search engines such as 
pubmed and Medline. Keywords employed were 
Neuroprotection and Glaucoma.
Results: There is ongoing research on neuroprotective 
agents in management of  glaucoma. A few of  the currently 
available anti glaucoma medications also have 
neuroprotective functions. The mainstay of  glaucoma 
management however remains lowering of  intraocular 
pressure. Nigerian literature on neuroprotection was not 
available.
Conclusion: It has become increasingly obvious that 
glaucoma represents a complex multifactorial disease that 
produces an accelerated rate of  ganglion cell atrophy 
related to a numerous pathogenic mechanisms that not 
only most certainly involve IOP, but also include defective 
auto regulation and ischaemia; neurotrophic factor 
deficiency; glutamate mediated excitotoxicity, immune 
related phenomenon; intracellular calcium influx and free 
3radical damage .IOP lowering still remains the mainstay of  
treatment. Neuroprotection has promise for preventing 
retinal cell ganglion death independent of  IOP.It therefore 
presents an exciting development in the pursuit for a 
treatment modality for this debilitating disease.
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1structural changes in the optic nerve head .
Glaucoma can also be viewed as a neurodegenerative 
disease that is often associated with high intraocular 
pressure (IOP), and in which at any time there are fibers 
(optic nerve axons) and cell bodies (retinal ganglion cells) 
that are vulnerable to degeneration and amenable to 
2protection . Recent evidence indicates that lowering IOP 
does not prevent progression in all patients and that 
progression can continue despite effective lowering of  
3IOP . This was illustrated in the Advanced Glaucoma 
4Treatment Study Trial , Collaborative Normal Tension 
5 Glaucoma Study and the Early Manifest Glaucoma 
6Study .
In recent years the focus of  glaucoma research has shifted 
toward neuroprotection, as the traditional strategies of  
lowering intraocular pressure have been shown to be 
unable to prevent progressive vision loss in some glaucoma 
7,8,9,10  patients . Most patients with elevated IOP never 
develop glaucoma, many patients who do not have 
statistically elevated pressure (low tension glaucoma) as 
well as many patients with controlled IOP continue to have 
11,12progressive vision loss . These observations suggest that 
an IOP independent mechanism contributes to disease 
13,14,15onset and progression .
Mechanisms of RGC Damage & Targets for 
1, 8,13,15,16Neuroprotective Agents  .
The exact mechanism(s) of  RGC damage in glaucoma is 
complex and unknown. Potential mechanisms for 
neuroprotection in terms of  pathways initiated by 
mechanical or ischemic injury, or by the toxic substances 
liberated by the primary insult to affected cells leading to 
secondary degeneration and apoptotic death.
A major destructive effect of  increased or fluctuating IOP is 
deformation of  the lamina cribrosa, mechanically 
compressing RGC axons. This reduces or blocks retrograde 
transport of  essential neurotrophic factors such as brain-
derived neurotrophic factor (BDNF), NGF, neurotrophin 
(NT)-3, NT-4 and NT-5, glial cell-derived neurotrophic 
factor, ciliary neurotrophic factor, and FGF-2, liberated by 
the superior colliculus and lateral geniculate body and 
transported to the RGC body by its axons. A lack of  
appropriate target-derived trophic support causes cells to 
undergo apoptotic degeneration. Supplementation of  these 
neurotrophic factors has been suggested to protect neurons 
from such degeneration
Another major theory in the etiology of  glaucoma is 
Neurotrophic Factors
Ischemia
Neuroprotection in Glaucoma: A Review
INTRODUCTION
Currently, glaucoma is recognized as an optic neuropathy. 
Selective death of  retinal ganglion cells (RGC) is the 
hallmark of  glaucoma, which is also associated with 
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vascular insufficiency at the optic nerve head. Arising from 
systemic hypotension, vasospasm or even mechanical 
compression of  the microvasculature at the lamina cribrosa, 
low perfusion of  the optic nerve head may cause RGC 
ischemia. This ischemic insult may reduce essential nutrients 
and substrates available for energy production in 
metabolically highly active neurons. Antivasospastic drugs 
such as calcium-channel blockers and some adrenergic 
antagonists have potential as neuroprotectants.
 
Increasingly, mitochondrial dysfunction is believed to 
contribute to the pathogenesis of  neurodegenerative 
disorders, including glaucoma. Mitochondria are the 
principal organelles for a cell's energy production (ATP)via 
the electron transport chain. This energy drives intracellular 
and intercellular signaling and is vital for cellular pump 
function, and thus cellular integrity. Mitochondrial 
dysfunction induces the intrinsic apoptotic pathway by up 
regulation of  NF-êB and proapoptotic genes. As 
mitochondrial dysfunction may be triggered by aging, 
ischemia and/or oxidative stress, novel methods such as 
caloric restriction (to try to retard aging), increasing optic 
head flow dynamics (with vasodilators) and decreasing 
oxidative stress (with antioxidants) may prove to be useful 
neuroprotective strategies
Any hypoxic environment critically drops ATP production 
with failure of  the vital sodiumpotassium pump of  both 
neurons and their supporting glia. Membranes depolarize 
with increased release and reduced clearance of  glutamate by 
dying RGCs or by metabolically compromised glial cells. As 
an essential CNS neurotransmitter and the main excitatory 
retinal neurotransmitter, glutamate is tightly regulated in the 
presynaptic cells; excessive levels of  glutamate are toxic not 
only to RGCs, but also to neighbouring healthy neurons. 
Excessive glutamate causes calcium influx through 
hyperactivation of  the N-methyl-D-aspartate (NMDA) 
receptor in a process termed excitotoxicity. NMDA receptor 
antagonists and some calcium-channel blockers may stabilize 
glutamate levels and prevent such cellular injury.
Overstimulation of  NMDA receptors also activates nitric 
oxide synthase (NOS), resulting in nitric oxide (NO) 
production. NO is a neuronal messenger critical for normal 
retinal neurotransmission and phototransduction. 
Unregulated, it has the potential to react with the superoxide 
anion to form peroxynitrite, a highly reactive oxidant species. 
Oxidative stress is the leading cause of  RGC loss, causing 
secondary degeneration to adjacent neurons either by direct 
neurotoxic insult through free-radical damage of  cell 
membranes, enzymes, proteins and DNA; or indirectly 
through induction of  glial dysfunction and activation of  
apoptotic pathways through its detrimental action on 
mitochondrial energy production. A wide variety of  free-
radical scavengers and NOS inhibitors are being investigated 
as potential therapeutic agents. 
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feature of  many neurodegenerative diseases, including 
Alzheimer's, Huntington's and Parkinson's, with an 
accumulation of  abnormal protein plaques in the brain. As 
Aâ has been linked to glaucomatous RGC apoptosis in a 
dose- and time-dependent manner, targeting different 
components of  the Aâ formation and aggregation pathways 
(e.g., using Aâ antibodies) may effectively reduce 
glaucomatous RGC apoptosis. 
Heat-shock proteins (Hsps) are chaperone proteins that 
facilitate nascent and stress-induced protein folding and 
unfolding, and restoration of  misfolded proteins. HspB1 
(Hsp27) is strongly induced during the stress response and has 
been associated with increasing the survival of  cells subjected 
to cytotoxic stimuli. Antibodies against Hsp27 have been 
identified in patients with glaucoma. It is unclear whether 
these autoantibodies exist as a result of  RGC injury, or effect a 
mimicked T-cell-mediated response to RGC damage. 
Development of  decoy antigens or vaccines may be a useful 
strategy for neuroprotection in glaucoma.
Retinal ganglion cells are not the only cells damaged in 
glaucoma: Müller glial cells, amacrine and bipolar cells are 
also injured. In the nonmyelinated region of  the optic nerve 
head, astrocytes are the major glial cells to provide support to 
neuronal axons, as well as interface between connective tissue 
and blood vessels. They help to maintain ion homeostasis and 
extracellular pH, as well as integrity of  the perineural 
extracellular matrix. To try to maintain homeostasis, 
quiescent astrocytes are transformed into a reactive state by 
liberated cytokines such as TGF, ciliary neurotrophic factor, 
GF and PDGF. Reactive astrocytes exhibit altered 
intercellular communication, migration, growth factor 
signaling, oxidative species buffering capacity and connective 
tissue properties at the optic nerve head. Modulation of  glial 
cell activity may therefore be useful as neuroprotective 
processes in the rescue of  neurons following an injurious 
insult. 
The final common pathway for any neuronal injury is 
necrosis or apoptosis, the latter playing a major role in RGC 
death in glaucoma. Apoptosis can be initiated by extrinsic or 
intrinsic pathways. Triggers for the extrinsic pathway include 
TNF-á, Fas ligand and TNF-related apoptosis-inducing 
ligand. The intrinsic pathway involves mitochondrial-
mediated events.  Regardless of  the initiating injury, there is 
activation of  the caspase cascade, increased expression of  
proapoptotic genes such as Bax/Bid down regulation of  
antiapoptotic genes such as Bcl-2/Bcl-xl, leading to 
noninflammatory programmed cell death.
1,3,7NEUROPROTECTIVE AGENTS
Numerous neuroprotective agents have been identified. In 
this section, we discuss some agents currently being explored 
for their neuroprotective properties.
Neurotrophins, such as NGF and BDNF, have been tested in 
animal models of  glaucoma and while some studies have 
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Nerve growth factor and BDNF bind high-affinity TrkA and -
B receptors selectively expressed on RGCs, as well as low-
affinity p75NTR receptors on Müller cells. Strategies to 
overcome neurotrophin deprivation include exogenous 
supplementation of  neurotrophins or direct activation of  its 
receptors. Brimonidine protects against many types of  ocular 
injury, including ischemia, compression, and transient and 
chronic ocular hypertension. The exact mechanism(s) are not 
17well defined  but include induction of  FGF and BDNF 
18synthesis  up regulation of  antiapoptotic genes such as Bcl-2 
and Bcl-XL, inhibition of  ischemia-induced glutamate 
19release or perhaps NMDA receptor modulation .
An increase in intracellular calcium is neurotoxic through 
activation of  calcium-dependent catabolic enzymes. 
Calcium-channel blockers such as memantine, flupirtine and 
dextromethorphan reduce calcium influx by their action at 
1the NMDA receptor . Other better-known calcium channel 
antagonists such as nifedipine, verapamil and diltiazem have 
20also been investigated, at least in normal-tension glaucoma . 
Although it remains unclear whether the activity of  calcium 
channel blockers is mediated through direct action on 
calcium status or indirectly through improved optic nerve 
blood flow, any benefit from these calcium channel blockers 
must be weighed against potential detrimental effects from 
systemic hypotension (including nocturnal) possibly 
contributing to ischemic stress at the optic nerve head by 
21reducing the optic nerve head perfusion pressure . 
Coenzyme Q10 (CoQ10) provides protection in 
neurodegenerative conditions such as Huntington's, 
Parkinson's and Alzheimer's disease. Several mechanisms of  
action are possible. First, as CoQ10 is an important 
component of  the mitochondrial electron transport chain, it 
potentiates energy production to overcome the consequences 
of  excessive glutamate. Second, it inhibits the transcription 
factor NF-êB, responsible for inflammation and 
autoimmune disease. Third, it inhibits opening of  the 
mitochondrial permeability transition pore (PTP), which is 
involved in cell death pathways. Finally, as a free-radical 
scavenger, CoQ10 prevents oxidative damage to critical 
1cellular structures caused by oxidative stress .
Vitamin E (á-tocopherol) is the major source of  lipid-soluble 
antioxidants in cells and may have vasoregulatory and 
22protein kinase C-mediated glutamate transport activity .  
Ginkgo biloba (EGb 761) increases the survival of  RGCs in 
experimental models. The precise mode of  action of  EGb 761 
is not fully understood, but it has putative properties as a 
potent antioxidant and free-radical scavenger, nitric oxide 
inhibitor, vasodilator, platelet-activating factor inhibitor and 
glutamate NMDA receptor inhibitor. Only limited data are 
1available to support its clinical use in glaucoma . 
23 Acetylcholinesterase Inhibitor .
In an in vivo study, the systemic administration of  
galantamine, an acetylcholinesterase inhibitor, was found to 
Calcium-channel Blockers
Antioxidants/Free-radical Scavengers
promote protection of  RGC soma and axons in a rat 
glaucoma model. Functional deficits caused by high IOP, 
assessed by recording visual evoked potentials from the 
superior colliculus, were improved by galantamine. These 
effects were not related to a reduction in IOP because 
galantamine did not change the pressure in glaucomatous 
eyes and it promoted neuronal survival after optic nerve 
axotomy, a pressure-independent model of  RGC death. 
These data provide the first evidence of  the clinical potential 
of  galantamine as neuroprotectant for glaucoma and other 
optic neuropathies, and identify muscarinic receptors as 
potential therapeutic targets for preventing vision loss in these 
blinding diseases.
Aminoguanidine is a potent inhibitor of inducible NOS 
(NOS-2) expressed on reactive astrocytes and some 
microglia, but its effectiveness in animal models of  glaucoma 
remains inconclusive. 
Memantine, an NMDA glutamate receptor antagonist, has 
been the most prominent neuroprotective agent in glaucoma. 
It was the first drug approved for use as a neuroprotective 
agent in moderate-to-severe Alzheimer's dementia. It is 
clinically tolerable and widely available. Evidence of  its 
usefulness in glaucoma arises from animal glaucoma models, 
where memantine was protective against retinal ganglion cell 
loss, neuronal shrinkage within the central visual pathway 
1and loss of  visual function .
 Dextromethorphan, a weakened narcotic commonly 
available as an anti-tussive, has NMDA antagonist activity, 
and has been explored for possible neuroprotection following 
1ischemic retinal injury .
Geranylgeraylacetone, an acyclic polyisoprenoid, induces up 
regulation of  HSP-72 expression in RGCs and protects them 
from glaucomatous damage in a rat glaucoma model. 
Although unused in glaucoma patients, it warrants 
consideration because it is administered orally, has low 
toxicity and is available as an anti-ulcer drug.
Amyloid â antibodies (Aâabs) have been shown to reduce 
RGC apoptosis for up to 16 weeks after a single dose in an 
ocular hypertensive rat glaucoma model. Aâabs may act by 
1clearing Aâ deposition and blocking Aâ aggregation .
Tumor necrosis factor ( TNF-á )is a critical mediator of  
cellular apoptosis as it induces both caspase-dependent and -
independent components of  the mitochondrial cell death 
1pathway .
Currently available glaucoma medications with 
3neuroprotective properties :
CONCLUSION:
Selective death of  ganglion cells is the hallmark of  glaucoma 
1,3,7,9,12,.The process of  cell death is thought to be biphasic: a 
primary injury responsible for initiation of  damage followed 
by secondary degeneration related to noxious environment 
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surrounding the degenerating cells. Neuroprotection is a 
process that attempts to preserve cells spared during the initial 
2insult but still vulnerable to damage .Several neuroprotective 
agents are still under investigation. A few antiglaucoma 
agents have been found to also possess neuroprotective 
3functions . Neuroprotection is an evolving area in the 
management of  glaucoma. The ideal neuroprotective agent 
when available will be of  great use in arresting the 
progression of  glaucoma, but for now, intraocular pressure 
lowering still remains the main stay of  treatment.
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